Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
Susan M. Landau,Susan M. Landau,Ming Lu,Abhinay D. Joshi,Michael J. Pontecorvo,Mark A. Mintun,John Q. Trojanowski,Leslie M. Shaw,William J. Jagust,William J. Jagust,William J. Jagust +10 more
Reads0
Chats0
TLDR
Analysis of agreement and disagreement between 2 biomarkers of β‐amyloid (Aβ) deposition in normal aging and dementia in a large multicenter study finds no agreement or disagreement between these biomarkers.Abstract:
Objective
We examined agreement and disagreement between two biomarkers of Aβ deposition (amyloid PET and CSF Aβ1-42) in normal aging and dementia in a large multicenter study.read more
Citations
More filters
Journal ArticleDOI
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
TL;DR: This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.
Journal ArticleDOI
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois,Harald Hampel,Harald Hampel,Howard Feldman,Philip Scheltens,Paul S. Aisen,Sandrine Andrieu,Hovagim Bakardjian,Habib Benali,Lars Bertram,Lars Bertram,Kaj Blennow,Karl Broich,Enrica Cavedo,Sebastian J. Crutch,Jean-François Dartigues,Charles Duyckaerts,Stéphane Epelbaum,Giovanni B. Frisoni,Serge Gauthier,Remy Genthon,Alida A. Gouw,Alida A. Gouw,Marie-Odile Habert,David M. Holtzman,Miia Kivipelto,Miia Kivipelto,Simone Lista,José Luis Molinuevo,Sid E. O'Bryant,Gil D. Rabinovici,Christopher C. Rowe,Stephen Salloway,Lon S. Schneider,Reisa A. Sperling,Reisa A. Sperling,Marc Teichmann,Maria C. Carrillo,Jeffrey L. Cummings,Cliff R. Jack +39 more
TL;DR: An updated review of the literature and evidence on the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage of Alzheimer's disease are provided.
Journal ArticleDOI
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Willemijn J. Jansen,Rik Ossenkoppele,Dirk L. Knol,Betty M. Tijms,Philip Scheltens,Frans R.J. Verhey,Pieter Jelle Visser +6 more
TL;DR: Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, apolipoprotein E [APOE] genotype, sex, and education, and presence of cognitive impairment.
Journal ArticleDOI
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
Elisabeth H. Thijssen,Elisabeth H. Thijssen,Renaud La Joie,Amy Wolf,Amelia Strom,Ping Wang,Leonardo Iaccarino,Viktoriya Bourakova,Yann Cobigo,Hilary W. Heuer,Salvatore Spina,Lawren VandeVrede,Xiyun Chai,Nicholas K. Proctor,David C. Airey,Sergey Shcherbinin,Cynthia Duggan Evans,John R. Sims,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Anna Karydas,Charlotte E. Teunissen,Joel H. Kramer,Lea T. Grinberg,William W. Seeley,Howie Rosen,Bradley F. Boeve,Bruce L. Miller,Gil D. Rabinovici,Jeffrey L. Dage,Julio C. Rojas,Adam L. Boxer +32 more
TL;DR: Plasma pTau181 concentrations are elevated specifically in patients diagnosed with Alzheimer’s disease compared to those diagnosed with frontotemporal lobar degeneration or elderly controls, supporting its further development as a blood-based biomarker for AD.
Journal ArticleDOI
Amyloid biomarkers in Alzheimer's disease.
Kaj Blennow,Kaj Blennow,Niklas Mattsson,Niklas Mattsson,Niklas Mattsson,Michael Schöll,Michael Schöll,Oskar Hansson,Henrik Zetterberg,Henrik Zetterberg +9 more
TL;DR: Amyloid biomarkers will be of special value in the clinic to identify patients with brain amyloid deposition at risk for progression to AD dementia, to enable initiation of treatment before neurodegeneration is too severe, and to monitor drug effects on Aβ metabolism or pathology to guide dosage.
References
More filters
Journal ArticleDOI
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Anne M. Fagan,Mark A. Mintun,Robert H. Mach,Sang-Yoon Lee,Carmen S. Dence,Aarti R. Shah,Gina N. LaRossa,Michael L. Spinner,William E. Klunk,Chester A. Mathis,Steven T. DeKosky,John C. Morris,David M. Holtzman +12 more
TL;DR: Amyloid‐β42 (Aβ42) appears central to Alzheimer's disease pathogenesis and is a major component of amyloid plaques, and its decrease may reflect plaques acting as an Aβ42 “sink,” hindering transport of soluble A β42 between brain and CSF.
Journal ArticleDOI
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark,Julie A. Schneider,Barry J. Bedell,Thomas G. Beach,Warren B. Bilker,Mark A. Mintun,Michael J. Pontecorvo,Franz Hefti,Alan Carpenter,Matthew Flitter,Michael J. Krautkramer,Hank F. Kung,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Eric M. Reiman,Simone P. Zehntner,Daniel Skovronsky +19 more
TL;DR: Evidence is provided that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life and for the prediction of progression to dementia.
Journal ArticleDOI
Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Anne M. Fagan,Catherine M. Roe,Chengjie Xiong,Mark A. Mintun,John C. Morris,David M. Holtzman +5 more
TL;DR: The very mildest symptomatic stage of AD exhibits the same CSF biomarker phenotype as more advanced AD, and CSF tau/Abeta(42) ratios show strong promise as antecedent (preclinical) biomarkers that predict future dementia in cognitively normal older adults.
Journal ArticleDOI
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging
John C. Morris,Catherine M. Roe,Chengjie Xiong,Anne M. Fagan,Alison Goate,David M. Holtzman,Mark A. Mintun +6 more
TL;DR: To examine interactions of apolipoprotein E (APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging, APOE genotype is linked with age-related changes in Alzheimer's disease.
Journal ArticleDOI
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
R. Motter,Carmen Vigo-Pelfrey,Dora Kholodenko,Robin Barbour,Kelly Johnson-Wood,Doug R. Galasko,Linda Chang,Bruce L. Miller,C. Clark,Robert C. Green,D. Olson,P. Southwick,R. Wolfert,B. Munroe,Ivan Lieberburg,Peter Seubert,Dale Schenk +16 more
TL;DR: It is interesting that CSF Aβ42 levels were found to be significantly lower in AD patients relative to controls, whereas total Aβ levels were not, and neither A β42 nor τ levels were apparently influenced by the ApoE genotype.
Related Papers (5)
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois,Bruno Dubois,Howard Feldman,Claudia Jacova,Harald Hampel,Harald Hampel,José Luis Molinuevo,Kaj Blennow,Steven T. DeKosky,Serge Gauthier,Dennis J. Selkoe,Randall J. Bateman,Stefano F. Cappa,Sebastian J. Crutch,Sebastiaan Engelborghs,Giovanni B. Frisoni,Nick C. Fox,Douglas Galasko,Marie-Odile Habert,Gregory A. Jicha,Agneta Nordberg,Florence Pasquier,Gil D. Rabinovici,Philippe Robert,Christopher C. Rowe,Stephen Salloway,Marie Sarazin,Stéphane Epelbaum,Stéphane Epelbaum,Leonardo Cruz de Souza,Leonardo Cruz de Souza,Leonardo Cruz de Souza,Bruno Vellas,Pieter Jelle Visser,Lon S. Schneider,Yaakov Stern,Philip Scheltens,Jeffrey L. Cummings +37 more
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more